menu
    • menu

    Company profile for Aisa Pharma

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aisa Pharma is dedicated to bringing new disease-modifying treatments to patients with rare serious diseases that are seldom the target of big pharma development programs and have few effective treatment options. The FDA defines rare diseases as being “orphan” when they affect <200,000 individuals in the United States. Aisa believes that select drugs belonging to a class of medicines called calcium channel blockers, which ...
    Aisa Pharma is dedicated to bringing new disease-modifying treatments to patients with rare serious diseases that are seldom the target of big pharma development programs and have few effective treatment options. The FDA defines rare diseases as being “orphan” when they affect <200,000 individuals in the United States. Aisa believes that select drugs belonging to a class of medicines called calcium channel blockers, which are commonly used to treat high blood pressure, can be “repurposed” to treat some of these rare diseases potentially providing further benefits when combined with other drugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aisa PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    33 Brimmer Street, Suite C Boston, MA 02108
    Telephone
    Telephone
    (617) 584-7292
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aisapharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aisa Pharma Reports Positive Phase 2 Trial Of AISA-021
    Aisa Pharma Reports Positive Phase 2 Trial Of AISA-021

    06 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-announces-encouraging-results-from-phase-2-reconnoiter-trial-of-aisa-021-cilnidipine-in-patients-with-systemic-sclerosisassociated-raynauds-phenomenon-302705901.html

    PR NEWSWIRE
    06 Mar 2026
    Share Share
    AISA Pharma Gets FDA Orphan Drug Status For AISA-021 In Systemic Sclerosis
    AISA Pharma Gets FDA Orphan Drug Status For AISA-021 In Systemic Sclerosis

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-receives-fda-orphan-drug-designation-for-aisa-021-for-treatment-of-systemic-sclerosis-302242199.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    AISA Pharma Announces Start of Ph2b Profervia® Study for Raynaud's Phenomenon
    AISA Pharma Announces Start of Ph2b Profervia® Study for Raynaud's Phenomenon

    21 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-announces-start-of-phase-2b-profervia-study-for-raynauds-phenomenon-in-systemic-sclerosis-ssc-301856151.html

    PR NEWSWIRE
    21 Jun 2023
    Share Share
    AISA Pharma Announces NIH-NINDS Award to investigate Profervia
    AISA Pharma Announces NIH-NINDS Award to investigate Profervia

    03 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aisa-pharma-announces-nih-ninds-award-to-investigate-profervia-as-a-non-opioid-analgesic-for-acute-and-chronic-pain-301788325.html

    PR NEWSWIRE
    03 Apr 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search